Special Issue "Pharmaceutical and Nutraceutical Manipulation of Gut Microbiota: Focus on Microbiome Characterization, Pharmacology, Diagnostics and Therapeutic Indications"

A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Microbiology".

Deadline for manuscript submissions: 30 April 2023 | Viewed by 1138

Special Issue Editor

Dr. Walid Mottawea
E-Mail Website
Guest Editor
School of Nutrition Sciences, Faculty of Health Sciences, University of Ottawa, 451 Smyth RD, Ottawa, ON K1H8M5, Canada
Interests: gut microbiome; inflammatory bowel diseases; 16S rRNA sequencing; brain-gut axis; probiotics; metagenomics; gut homeostasis; systems biology; bacterial genomics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Over the past two decades, advances in omics technology have allowed comprehensive characterizations of the gut microbiome in many health disorders. Gut microbiomes interact with the host through their metabolites, defense against pathogens, and/or immunological promotion. Perturbation of host–microbiome crosstalk has been associated with different health disorders, including irritable bowel syndrome, inflammatory bowel diseases, diabetes, Clostridium difficile infection, and mental health disorders, in addition to the medications used to treat these disorders, such as antidepressants. While some therapeutics, such as some antivirals, are metabolized by the gut microbiota, others, such as antidepressants, affect the gut microbiota diversity. Therefore, the focus of interest of the current wave of microbiome research is investigating how to manipulate the gut microbiome consortium to promote human health and augment the efficiency of other therapeutics. Manipulation of the gut microbiome can be achieved through restoring microbiota diversity and composition or inducing certain functional activities. Several targeted and non-targeted approaches are being tested for their efficiency in modulating the microbiome balance. These approaches include fecal microbiota transplant (FMT) and prebiotic, probiotic, and CRISPR-Cas9-engineered phage. In addition, xenobiotics–gut microbiota interaction is bidirectional. The purpose of this Special Issue is to create a collection of scientific reports that help us to understand the microbiome’s therapeutic potential in different disorders. We invite original articles and extensive reviews in the areas of microbiome characterization, biomarker identification, microbiome pharmacodynamics and pharmacokinetics, and microbiome-based therapeutic manipulations. Any type of article on host–microbiome crosstalk is welcome.

This collection is the second edition of the previous one "Gut Microbiome Manipulation: Focus on Microbiome Characterization, Diagnostics and Therapeutic Indications": https://www.mdpi.com/journal/biology/special_issues/GMMFOMCDATI.

Dr. Walid Mottawea
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • gut microbiome
  • microbiome pharmacodynamics and pharmacokinetics
  • fecal microbiota therapy
  • prebiotics
  • probiotics
  • microbiome therapeutics

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Survival and Interplay of γ-Aminobutyric Acid-Producing Psychobiotic Candidates with the Gut Microbiota in a Continuous Model of the Human Colon
Biology 2022, 11(9), 1311; https://doi.org/10.3390/biology11091311 - 04 Sep 2022
Cited by 1 | Viewed by 983
Over decades, probiotic research has focused on their benefits to gut health. Recently, the gut microbiota has been proven to share bidirectional connections with the brain through the gut–brain axis. Therefore, the manipulation of this axis via probiotics has garnered interest. We have [...] Read more.
Over decades, probiotic research has focused on their benefits to gut health. Recently, the gut microbiota has been proven to share bidirectional connections with the brain through the gut–brain axis. Therefore, the manipulation of this axis via probiotics has garnered interest. We have recently isolated and characterized in vitro probiotic candidates producing γ-aminobutyric acid (GABA), a major neuromodulator of the enteric nervous system. This study investigates the growth and competitiveness of selected GABA-producing probiotic candidates (Bifidobacterium animalis, Streptococcus thermophilus, and Lactobacillus delbrueckii subsp. bulgaricus) in the presence of human gut microbiota ex vivo in a model mimicking physiological and microbiological conditions of the human proximal colon. Supplementation with GABA-producing probiotic candidates did not affect the overall gut microbiota diversity over 48 h of treatment. However, these candidates modulated the microbiota composition, especially by increasing the Bacteroidetes population, a key gut microbe associated with anti-inflammatory activities. The level of microbiota-generated SCFAs within 12 h of treatment was also increased, compared to the control group. Results from this study demonstrate the probiotic potential of the tested GABA-producing bacteria and their impact on gut microbiota structure and metabolism, suggesting their suitability for gut health-promoting applications. Full article
Show Figures

Figure 1

Back to TopTop